Author

Harshal Chaudhari

Observed institutions: Apollo Hospitals, Merck KGaA, Darmstadt (Germany), Apollo Hospitals, Apollo Hospitals, Merck Specialities Pvt. Ltd. (India)

ORCID: 0000-0001-5542-7544

Observed ORCID: 0000-0001-5542-7544

OpenAlex ID: A5022046094

Adverse drug reactions reported in Indira Gandhi Government Medical College and Hospital, Nagpur.

2011 · Meena Shrivastava, Ganesh Uchit, et al. · PubMed · 31

Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India

2016 · Mathew John, Ekaterina Koledova, et al. · International Journal of Endocrinology · 17

A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin

2023 · Aditi Jain, Abhay Vispute, et al. · Diabetes Therapy · 14

A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial

2024 · Awadhesh Kumar Singh, Rakesh Sahay, et al. · International Journal of Diabetes in Developing Countries · 11

Diagnosis and Management of Hypothyroidism: Addressing the Knowledge–Action Gaps

2018 · Sanjay Kalra, A. K. Das, et al. · Advances in Therapy · 11

Evolving landscape of multiple sclerosis in India: Challenges in the management

2018 · Harshal Chaudhari, Sudhir Kumar, et al. · Annals of Indian Academy of Neurology · 10

Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific

2023 · Saumitra Ray, Tiny Nair, et al. · Current Medical Research and Opinion · 8

Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India

2026 · Sunil Panda, Shrinivas Chavan, et al. · Drugs - Real World Outcomes · 1

Importance of right communication with healthcare providers and patients about the new levothyroxine formulation: an expert opinion from Asia Pacific Thyroid Advisory Board

2024 · Salman Razvi, Nemencio Nicodemus, et al. · Current Medical Research and Opinion · 1

Works count: 10

Citation count: 104

H-index: 7

I10-index: 6